RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry Into a Material Definitive Agreement
On December 1, 2017, Rich Pharmaceuticals, Inc. (the “Company”) extended the Employment Agreement for a one-year term with Ben Chang, the Company’s Chief Executive Officer. The foregoing is only a brief description of the material terms of the Employment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits which are filed as an exhibit to this Current Report.
SECTION 5 – Corporate Governance and Management
Item 5.02 Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
The disclosure in Item 1.01 regarding the Employment Agreement for Ben Chang is incorporated herein by reference.
On December 1, 2017, the Board of Directors of the Company extended Ben Chang’s Employment Agreement as the Chief Executive Officer of the Company.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| No. | Description |
| 10.73 | Ben Chang Employment Extension 2017 |
Rich Pharmaceuticals, Inc. ExhibitEX-10.73 2 ex10_73.htm EX-10.73 Dear Ben Chang,…To view the full exhibit click here
About RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA)
Rich Pharmaceuticals, Inc. is a development-stage company. The Company is a biopharmaceutical company focused on developing and commercializing therapies in oncology. The Company is developing 12-O-tetradecanoylphorbol-13-acetate (RP-323) for the treatment of Hodgkin’s lymphoma (HL), Acute Myelogenous Leukemia (AML) and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. RP-323 is a naturally occurring compound. RP-323 converts cancer cells to normal cells, a process called differentiation. It is also observed in some instances to cause cancer cell death. Clinical studies in over 100 cancer patients demonstrated the ability of RP-323 to stimulate the production of white blood cells and neutrophils. The Company has no products ready for commercialization. The Company had no revenues during the period ending March 31, 2016.
